Pfiz­er throws its weight be­hind LNP play­er eye­ing mR­NA treat­ments for CF, PCD

David Lock­hart did not see the me­te­oric rise of mes­sen­ger RNA and lipid nanopar­ti­cles com­ing.

Thanks to the world­wide fight against Covid-19, mR­NA — the ge­net­ic code that can be en­gi­neered to turn the body in­to a mi­ni pro­tein fac­to­ry — and LNPs, those tiny bub­bles of fat car­ry­ing those in­struc­tions, have found their way in­to hun­dreds of mil­lions of peo­ple. With­in the biotech world, pi­o­neers like Al­ny­lam and In­tel­lia have demon­strat­ed just how ver­sa­tile LNPs can be as a de­liv­ery ve­hi­cle for any­thing from siR­NA to CRISPR/Cas9.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER